Selasa, 11 Juni 2013

Campaigners celebrate as Plan B morning-after pill made available to all

Campaigners celebrate as Plan B morning-after pill made available to all

Campaigners have welcomed as a "huge breakthrough" the Obama administration's decision to give up its fight to limit the sale of a morning-after pill.

Plan B will soon become available to women and girls of all ages without a prescription, following a decade-long battle which pitted successive White House administrations and the Food and Drug Administration against reproductive-rights campaigners, physicians and women's groups seeking to make emergency contraception universally available. Such groups have long argued that since morning-after pills such as Plan B One Step are very time sensitive and safe, they should be as available as over-the-counter pain relievers. Plan B and similar medicines which delay ovulation are most effective within 72 hours of unp rotected sex.

In a letter on Monday, the Justice Department said it planned to comply with a court's ruling to allow unrestricted sales of Plan B One Step and said it would withdraw its appeal against it. It said it would put into place Judge Edward Korman's order to have the FDA approve the pill for non-prescription use.

In 2009, the pill became available without prescription to women over the age of 17 who present proof of identification. In Plan B, the synthetic hormone levonorgestrel acts to postpone ovulation, preventing sperm from coming into contact with an egg. It does not cause an abortion or otherwise end a pregnancy and will not work if a woman is already pregnant.

Reproductive-rights campaigners, who first petitioned to have Plan B available over the counter and without a prescription in 2001, said the administration should also make other, cheaper versions of emergency contraception available. Other brands of emergency contraceptives will not be similarly available; nor will a two-pill version of Plan B, which is manufactured by an Israel-based pharmaceutical firm, Teva.

Nancy Northup, president and chief executive of the Center for Reproductive Rights, said she would continue to fight for fair treatment for "women who want and need more affordable options".

"Now that the appeals court has forced the federal government's hand," she said, "the FDA is finally taking a significant step forward by making Plan B One-Step available over the counter for women of all ages. But the Obama administration continues to unjustifiably deny the same wide availability for generic, more affordable brands of emergency contraception."

Korman, who has been highly critical of the government's actions during the case, has written in court documents that the health and human services secretary, Kathleen Sebelius, acted in "bad faith" a nd was "politically motivated" when she overruled the FDA's 2011 effort to make the drugs available to all ages without a prescription. Barack Obama publicly supported Sebelius's decision and spoke of his two daughters, saying the thought of the drug being available without a prescription would make him uncomfortable.

On 5 April, Judge Korman issued an order that the drugs must be sold over the counter without age restrictions and within 30 days. Instead, the FDA lowered the minimum purchasing age from 17 to 15. Korman has also said that statistics show the FDA's recent decision places "a disproportionate burden" on African Americans and the less well off. This, he said, is in part because the FDA decision does not apply to generic drugs, which are typically le ss expensive.

In Monday's letter to Korman, Loretta Lynch, US attorney for the eastern district of New York, writes that other manufacturers could submit approval applications, but adds that the FDA might grant Teva "marketing exclusivity". Lynch states that the government and the FDA believe that only the one-step pill should be available over the counter, because of "significant differences" between Plan B One Step and the two-step product. There was, it said, fewer data on the use of the two-step product as a non-prescription drug by younger adolescents.

Dr Tracy Wilkinson, a paediatrician and member of Physicians for Reproductive Health, said the administration's original appeal had surprised the medical profession, because it had pledged not to put politics ahead of science. She said: "There have been mountains of evidence about the safety and efficacy of this medicine for women of all ages and so restricting it on the basis of anyone's age had no scientific basis."

Dr Wilkinson said that multiple studies had also shown that "women of all ages" can read a label and take medicine such as Plan B, which involves taking two tablets.

In a statement, Cecile Richards, the president of the Planned Parenthood Federation of America said: "This is a huge breakthrough for access to birth control and a historic moment for women's health and equity. The FDA's decision will make emergency contraception available on store shelves, just like condoms, and women of all ages will be able to get it quickly in order to prevent unintended pregnancy."

Unrestricted access to emergency contraception is supported by an array of medical groups, including the American Medical Association. Last year, the American Academy of Pediatrics said underage teens should be given emergency contraception before they start to have se x, in order to tackle teenage pregnancies.

In the US, teenage pregnancies have dropped over the last 20 years. But according to a study published last month by the Center for Disease Control and Prevention, the country still has one of the highest rates of such pregnancies in the developed world. There were 31.3 pregnancies per 1,000 teenagers in the US in 2011, compared to 25 per 1,000 in Britain in 2009 and 10.2 in France in 2008, according to UN figures.

Campaigners celebrate as Plan B morning-after pill made available to all

Campaigners celebrate as Plan B morning-after pill made available to all

Campaigners have welcomed as a "huge breakthrough" the Obama administration's decision to give up its fight to limit the sale of a morning-after pill.

Plan B will soon become available to women and girls of all ages without a prescription, following a decade-long battle which pitted successive White House administrations and the Food and Drug Administration against reproductive-rights campaigners, physicians and women's groups seeking to make emergency contraception universally available. Such groups have long argued that since morning-after pills such as Plan B One Step are very time sensitive and safe, they should be as available as over-the-counter pain relievers. Plan B and similar medicines which delay ovulation are most effective within 72 hours of unp rotected sex.

In a letter on Monday, the Justice Department said it planned to comply with a court's ruling to allow unrestricted sales of Plan B One Step and said it would withdraw its appeal against it. It said it would put into place Judge Edward Korman's order to have the FDA approve the pill for non-prescription use.

In 2009, the pill became available without prescription to women over the age of 17 who present proof of identification. In Plan B, the synthetic hormone levonorgestrel acts to postpone ovulation, preventing sperm from coming into contact with an egg. It does not cause an abortion or otherwise end a pregnancy and will not work if a woman is already pregnant.

Reproductive-rights campaigners, who first petitioned to have Plan B available over the counter and without a prescription in 2001, said the administration should also make other, cheaper versions of emergency contraception available. Other brands of emergency contraceptives will not be similarly available; nor will a two-pill version of Plan B, which is manufactured by an Israel-based pharmaceutical firm, Teva.

Nancy Northup, president and chief executive of the Center for Reproductive Rights, said she would continue to fight for fair treatment for "women who want and need more affordable options".

"Now that the appeals court has forced the federal government's hand," she said, "the FDA is finally taking a significant step forward by making Plan B One-Step available over the counter for women of all ages. But the Obama administration continues to unjustifiably deny the same wide availability for generic, more affordable brands of emergency contraception."

Korman, who has been highly critical of the government's actions during the case, has written in court documents that the health and human services secretary, Kathleen Sebelius, acted in "bad faith" a nd was "politically motivated" when she overruled the FDA's 2011 effort to make the drugs available to all ages without a prescription. Barack Obama publicly supported Sebelius's decision and spoke of his two daughters, saying the thought of the drug being available without a prescription would make him uncomfortable.

On 5 April, Judge Korman issued an order that the drugs must be sold over the counter without age restrictions and within 30 days. Instead, the FDA lowered the minimum purchasing age from 17 to 15. Korman has also said that statistics show the FDA's recent decision places "a disproportionate burden" on African Americans and the less well off. This, he said, is in part because the FDA decision does not apply to generic drugs, which are typically le ss expensive.

In Monday's letter to Korman, Loretta Lynch, US attorney for the eastern district of New York, writes that other manufacturers could submit approval applications, but adds that the FDA might grant Teva "marketing exclusivity". Lynch states that the government and the FDA believe that only the one-step pill should be available over the counter, because of "significant differences" between Plan B One Step and the two-step product. There was, it said, fewer data on the use of the two-step product as a non-prescription drug by younger adolescents.

Dr Tracy Wilkinson, a paediatrician and member of Physicians for Reproductive Health, said the administration's original appeal had surprised the medical profession, because it had pledged not to put politics ahead of science. She said: "There have been mountains of evidence about the safety and efficacy of this medicine for women of all ages and so restricting it on the basis of anyone's age had no scientific basis."

Dr Wilkinson said that multiple studies had also shown that "women of all ages" can read a label and take medicine such as Plan B, which involves taking two tablets.

In a statement, Cecile Richards, the president of the Planned Parenthood Federation of America said: "This is a huge breakthrough for access to birth control and a historic moment for women's health and equity. The FDA's decision will make emergency contraception available on store shelves, just like condoms, and women of all ages will be able to get it quickly in order to prevent unintended pregnancy."

Unrestricted access to emergency contraception is supported by an array of medical groups, including the American Medical Association. Last year, the American Academy of Pediatrics said underage teens should be given emergency contraception before they start to have se x, in order to tackle teenage pregnancies.

In the US, teenage pregnancies have dropped over the last 20 years. But according to a study published last month by the Center for Disease Control and Prevention, the country still has one of the highest rates of such pregnancies in the developed world. There were 31.3 pregnancies per 1,000 teenagers in the US in 2011, compared to 25 per 1,000 in Britain in 2009 and 10.2 in France in 2008, according to UN figures.

Sabtu, 08 Juni 2013

Second US family urges change to children's organ transplant policy

Second US family urges change to children's organ transplant policy

PHILADELPHIA | Sat Jun 8, 2013 10:24pm EDT

PHILADELPHIA (Reuters) - A second family has stepped forward in the public fight to change a donor-organ policy that places sick children younger than 12 years of age at the bottom of the adult transplant list, regardless of the severity of their illness.

The mother of Javier Acosta, 11, who suffers from cystic fibrosis and needs a lung transplant, urged policymakers on Saturday to adopt new rules to make a life-saving adult lung more readily available to her gravely ill son.

"If Javier does not receive a transplant, he will die," Milagros Martinez said during a news conference in Philadelphia. "I say that's unfair because of a policy. It shouldn't be that way."

The family of Sarah Murnaghan, 10, who like Javier is suffering from cystic fibrosis, is also publicly calling for a change in transplant list policies administered by the Organ Transplant and Procurement Network.

The Murnaghan family efforts have garnered national media attention and scrutiny of lawmakers on Capitol Hill, some of whom have called on U.S. Health and Human Services Secretary Kathleen Sebelius to intervene.

Last week, U.S. District Judge Michael Baylson gra nted the two families a temporary court order barring enforcement of a policy that places children under age 12 at the bottom of the adult lung transplant list, regardless of their illness.

The Murnaghan and Acosta children are both awaiting lung transplants at the Children's Hospital of Philadelphia. While each is eligible for donor lungs from children, those are rare.

The lawsuits have led some to voice concerns that adding children to adult transplant rosters could end up pushing deserving older patients farther down the list.

But Stephen Harvey, a lawyer for both families, said his clients want a policy change based on patients' relative conditions, not their ages.

"We're seeking that the system allocate a lung to Javier based on the severity of his condition," Harvey said. "So if there's an adult who's more severe than him, that adult gets the lung. We're not asking to jump to the front of the l ine."

The executive committee of the Organ Transplant Network is due to meet on Monday, at which time it could announce a review of the transplant rules. Failing that, a hearing to review the restraining order is scheduled for June 14 before Judge Baylson.

It was unclear how many children would be affected by a shift in rules. Harvey said there are 16 children aged from 5 to 10 currently seeking lung transplants, and that 23 such procedures were performed on children in 2011.

(Editing by Steve Gorman and Eric Walsh)

Obama Promotes Health Care to California; New Plans Begin on October 1

Obama Promotes Health Care to California; New Plans Begin on October 1

Obama Promotes Health Care to California; New Plans Begin on October 1

By Julie S | Jun 08, 2013 09:13 AM EDT

Obama Promotes Health Care to California; New Plans Begin on October 1

U.S President Barack Obama gave a speech to the Californians announcing his healthcare policy changes effective October 1.

"If you're one of 6 million Californians or tens of millions Americans who don't currently have health insurance, you'll soon be able to buy quality, affordable care just like everybody else," said Obama during his speech in San Jose, CA.

Despite the criticisms that the Affordable Care Act is not really affordable, the president was firm that it is valuable to the Americans. The act, also known as Obamacare, was implemented since 2010 regulating the healthcare system of the country. T

Share This Story

he objective was to increase the coverage and cut the overall costs of health care to make it affordable for the general public. To date, there are already 21 provisions under this law with 10 of it already in place and 11 future-dated. Full provision will be completed by 2020.

The provision that will be implemented on October 1 will allow people looking to buy individual health insurance to enroll in subsidized plans offered through state-based exchanges, with coverage beginning in January 2014.

California has the most Americans with about 12 percent of the U.S population as of 2012 based on the U.S Census Bureau database. The government believes that the state will play a significant role on the success of Obamacare if all uninsured will be able to purchase a healthcare plan.

Based on the records of California Healthcare Foundation in 2011, California had the most number of health uninsured people in the country and it continues to rise. Only 22 percent of people under age 65 have a healthcare insurance. To date, about 6 million residents don’t have insurance.

The healthcare supporters expect to have an additional 1 million enrollment for healthcare once the provision begins on Oct. 1. Opponents believe it's unlikely as the insurance prices will increase before then. Since May 23, it has been reported that the prices have increased by up to 146 percent which will cost a 40-year-old to pay between $40 to $300 per month for a mid-level plan, depending on the income and subsidies.

Kamis, 06 Juni 2013

Komen foundation cancels breast cancer walk in 7 cities

Komen foundation cancels breast cancer walk in 7 cities

Nightly News   |  June 05, 2013

Donations to the Susan G. Komen Foundation have fallen ever since the charity’s brand was damaged when their founder tried to deny funds to Planned Parenthood. NBC’s Brian Williams reports.

Share This:

Rabu, 05 Juni 2013

Komen cancels 3-Day walk in District, six other cities in 2014

Komen cancels 3-Day walk in District, six other cities in 2014

Spokeswoman Andrea Rader cited economic uncertainty and competition from other charities as factors in the decision â€" the same reasons Komen has cited for the drop in fundraising since founder Nancy Brinker sparked national headlines in February 2012 when she unsuccessfully attempted to deny funds to Planned Parenthood.

“Many participants have reported that enthusiasm for the series remains very high, but it is more difficult for people to donate at levels they had in the past,” the statement said. It said participation in the past four years has made it difficult to sustain the event in 14 cities. “We hope to one day return to a larger number of markets, but believe strongly that this adjustment will allow us to return the greatest amount of dollars to the cause at this time.”

The announcement does not affect the 3-Day events scheduled for this year or other Komen events or services. Komen’s Washington 3-Day walk for this year will take place beginning Oct. 11.

Komen will continue to host the 3-Day events in 2014 in Atlanta, Dallas-Fort Worth, Michigan, Philadelphia, San Diego, Seattle and Minneapolis-St. Paul.

But next year, in addition to dropping Washington, Komen will not host 3-Day events in Arizona, Boston, Chicago, Cleveland, the Tampa Bay area and San Francisco.

The 3-Day events, which require participants to raise at least $2,300, are top revenue sources but expensive to organize, according to people familiar with Komen’s fundraising. Participants walk about 20 miles each of three days.

The events also tend to attract the most dedicated supporters, many of whom also support Planned Parenthood and were among those most upset by the controversy, according to sources familiar with Komen’s fundraising.

By comparison, next year’s Avon Walk for Breast Cancer will take place in the same eight cities as the group’s 2013 events â€" Houston, Washington, Boston, Chicago, San Francisco, New York, Charlotte and Santa Barbara, Calif., an Avon spokeswoman said.

“Our participation levels are on par with last year,” she said. Avon’s walk in Washington, which took place this past May, raised $4.5 million, compared to $5 million in 2012.

Komen’s annual Race for the Cure in Washington took place a week later. It had fewer participants than in previous years â€" about 21,000 people, down from 27,000 last year and nearly 40,000 in 2011. The race raised $5 million in 2011, $2 million last year and about $1.5 million this year, although this year’s tally is not final.

The dip in fundraising forced Komen to tap its reserves last year to fund research and other g rants, angering some affiliates, according to a source familiar with fundraising.

Rader denied that affiliates were concerned. “I don’t think anybody was particularly upset,” she said. “We have fairly substantial reserves and we had to tap them to help with our mission.”

Several senior executives who were well regarded at Komen’s Dallas headquarters have left or announced their departures in recent months. They are British Robinson, who oversaw Komen’s global operations; Lynn Erdman, who oversaw community health; and Carol Corcoran, senior vice president for Komen’s 120 affiliates.

Rader said Robinson’s and Corcoran’s departures were for personal reasons, while Erdman’s was the result of a restructuring.

While many of senior executives and board members have left, founder Brinker remains in place. Her $684,717 salary in fiscal 2012 continues to draw criticism.

FDA panel revisits Avandia; likely too late for diabetes drug

FDA panel revisits Avandia; likely too late for diabetes drug

Wed Jun 5, 2013 7:02am EDT

(Reuters) - A panel of medical advisers to the U.S. Food and Drug Administration will revive a six-year-old debate over the safety of GlaxoSmithKline Plc's Avandia diabetes drug, but the two-day meeting that starts on Wednesday is not expected to greatly boost sales of the onetime blockbuster product.

Avandia's U.S. patent lapsed in 2011, a year after the FDA heavily restricted its use due to ambiguity about possible increased risk of heart attack and stroke seen in a large trial called RECORD, as well as a review of dozens of other studies.

The drug, which was withdrawn from the market in Europe in 2010 and is taken now by only 3,000 Americans, was once the world's biggest-selling treatment for type 2 diabetes, with sales of $3.2 billion in 2006.

No generic drugmakers have introduced cheaper copycats in the U.S. market and Glaxo has said it has no plans to promote Avandia again, even if the panel of FDA medical advisers recommends lifting restrictions on sales of the drug.

"The FDA is putting significant resources behind this meeting, but even if they allow Avandia to return to full marketing strength, I don't think that would do much for Glaxo from a business standpoint," said Morningstar ana lyst Damien Conover.

Conover said there was only a "slight" chance that the meeting will prompt the FDA to greatly ease the sales restrictions.

"But if they do, that could signal that the FDA is a little more willing to accept more side effects than it has in the past," Conover said.

Glaxo has settled lawsuits filed by tens of thousands of U.S. patients who had taken Avandia and claimed Glaxo failed to inform them about risks. Several thousand other cases remain pending.

The RECORD safety trial was required by European regulators due to concerns that drugs in its class - called thiazolidinediones - could increase risk of heart failure.

The trial met its primary objective by showing that Avandia, when combined with either metformin or a member of an older class of diabetes pills called sulfonylureas, was at least as safe as the combination of metformin and a sulfonylurea.

< /span>

But the FDA clamped down on Avandia's use in September 2010 after most members of an FDA advisory panel voted that the RECORD data raised significant concerns that Avandia could indeed pose greater risk of heart attack and stroke than standard treatments, including Takeda Pharmaceutical Co's Actos (pioglitazone), another thiazolidinedione.

Although the FDA allowed Avandia to remain on the U.S. market, the agency commissioned the Duke Clinical Research Institute to analyze results of the RECORD trial to better assess Avandia's safety and to examine criticisms that the trial was poorly designed and its data was mishandled.

But the FDA on Monday, in a briefing document ahead of the two-day meeting this week, said the study's methods and analyses passed muster with the Duke group, part of Duke University's Medical School. Moreover, it said the group appeared to agree that Avandia was not associated in the RECORD trial with increased risk of heart attacks and stroke.

Avandia had been on a downhill slide since 2007, when Dr. Steven Nissen, head of cardiology at the Cleveland Clinic, reported results of a so-called meta-analysis in which data from 42 studies was pooled and analyzed. It showed a 43 percent increased risk of heart attack from Avandia.

Sales of Avandia, which was approved in 1999 and makes patients more sensitive to their own insulin, plunged following the negative publicity, and the FDA now requires heart-safety data for new diabetes drugs because of the Avandia experience.

Glaxo last July agreed to pay $3 billion to settle what U.S. officials called the largest case of healthcare fraud in U.S. history. The agreement resolved allegations that Glaxo failed through 2007 to provide the FDA safety data on Avandia, and that the company improperly marketed other drugs.

(Reporting By Ransdell Pierson in New York; Editing b y Tim Dobbyn)